I
22.77
0.75 (3.41%)
| Penutupan Terdahulu | 22.02 |
| Buka | 22.28 |
| Jumlah Dagangan | 198,554 |
| Purata Dagangan (3B) | 1,739,023 |
| Modal Pasaran | 3,991,046,656 |
| Harga / Buku (P/B) | 7.70 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 Feb 2026 |
| EPS Cair (TTM) | -2.73 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.01% |
| Nisbah Semasa (MRQ) | 11.16 |
| Aliran Tunai Operasi (OCF TTM) | -375.87 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -227.82 M |
| Pulangan Atas Aset (ROA TTM) | -37.97% |
| Pulangan Atas Ekuiti (ROE TTM) | -62.46% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Immunovant, Inc. | Menurun | Menurun |
AISkor Stockmoo
-1.5
| Konsensus Penganalisis | -0.5 |
| Aktiviti Orang Dalam | -3.0 |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 0.5 |
| Purata | -1.50 |
|
Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn). |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 58.17% |
| % Dimiliki oleh Institusi | 55.78% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 33.00 (JP Morgan, 44.93%) | Beli |
| Median | 24.50 (7.60%) | |
| Rendah | 16.00 (Truist Securities, -29.73%) | Pegang |
| Purata | 24.50 (7.60%) | |
| Jumlah | 1 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 16.81 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Truist Securities | 14 Oct 2025 | 16.00 (-29.73%) | Pegang | 17.49 |
| JP Morgan | 30 Sep 2025 | 33.00 (44.93%) | Beli | 16.12 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| FROMKIN ANDREW J. | - | 22.75 | -22,249 | -506,165 |
| HUGHES DOUGLAS J. | - | 22.75 | -15,000 | -341,250 |
| Jumlah Keseluruhan Kuantiti Bersih | -37,249 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -847,415 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 22.75 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| HUGHES DOUGLAS J. | Pengarah | 01 Dec 2025 | Jual automatik (-) | 15,000 | 22.75 | 341,250 |
| FROMKIN ANDREW J. | Pengarah | 01 Dec 2025 | Jual automatik (-) | 22,249 | 22.75 | 506,165 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 10 Nov 2025 | Pengumuman | Immunovant Provides Corporate Updates and Reports Financial Results for the Second Quarter Ended September 30, 2025 |
| 27 Oct 2025 | Pengumuman | Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |